zinc dichloride
Approved
Jul 29, 1955
Gluconic acid is a natural compound produced from glucose through a simple dehydrogenation reaction catalysed by glucose oxidase. Gluconic acid and its salts are used in the formulation of food, pharmaceutical and hygienic products. — NCATS
Clinical trial activity
109 trials · 142 clinical orgs · 18 marketing orgs
Earliest trial started Oct 1, 1993 (NCT00004338)
Timeline
1950s
- Jul 29, 1955
Earliest FDA Approval
1980s
- Feb 22, 1980
Armour & Company — Marketing Organization
- Feb 22, 1980
Armour & Company — NDA Secondary Org
- Jun 26, 1986
Hospira — NDA Secondary Org
- May 5, 1987
Abraxis — NDA Secondary Org
1990s
- Jan 28, 1997
Teva — First NDA Organization
- Jan 28, 1997
Teva — NDA Secondary Org
- Jan 28, 1997
Teva — NDA Organization
- Jan 28, 1997
Eton Pharmaceuticals, Inc. — Marketing Organization
- Jan 1, 1999
Earliest Phase 3 Sponsor(trial)
2010s
- Jul 18, 2019
Sankyo — Marketing Organization
- Jul 18, 2019
Daiichi Sankyo — NDA Secondary Org
2020s
- May 21, 2021
Exela Pharma Sciences, LLC. — Marketing Organization
- May 3, 2022
Gland Pharma Ltd — Marketing Organization
- May 3, 2022
Fosun — Marketing Organization
- Dec 27, 2022
Fresenius — Marketing Organization
- Aug 22, 2023
Zydus Discovery DMCC — Marketing Organization
- Jun 10, 2024
Apotex — Marketing Organization
- Jul 5, 2024
Nivagen Pharmaceuticals Inc. — Marketing Organization
- Jul 17, 2024
Somerset Pharmaceuticals — Marketing Organization
- Apr 14, 2025
Apicore — Marketing Organization
- May 1, 2025
Aspiro — Marketing Organization
- Jun 10, 2025
STIRA — Marketing Organization
Indications
Studied for
- Anaplasia · Phase 1
- Asthenozoospermia · Phase 2
- Atrophic Vaginitis · Phase 3
- Bacterial Infections · Phase 2/Phase 3
- Bone Marrow Transplantation · Phase 2/Phase 3
- Botulinum Toxins · Early Phase 1
- Brain Neoplasms · Phase 2
- Bronchiolitis · Phase 3
- Canavan Disease · Phase 2
- Carcinoma, Verrucous · Phase 2
- Cardiomyopathies · Phase 1
- Cataract · Phase 2
- Cholera · Phase 1/Phase 2
- Chronic Periodontitis · Phase 3
- Colorectal Surgery · Phase 4
- Conjunctivitis, Bacterial · Phase 4
- Cough · Phase 2
- COVID-19 · Phase 3
- Critical Illness · Phase 1/Phase 2
- Death · Phase 3
- Deficiency Diseases · Phase 2
- Dehydration · Phase 2/Phase 3
- Dermatitis · Phase 3
- Dermatology · Phase 4
- Diabetes Mellitus, Type 2 · Phase 4
- Diabetic Retinopathy · Phase 2
- Diarrhea · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 3
- Dysgeusia · Phase 3
- Eczema · Phase 2
- Enzymes · Phase 2
- Epiretinal Membrane · Phase 4
- Esophageal Neoplasms · Phase 2
- Facial Neuralgia · Early Phase 1
- Feeding and Eating Disorders · Phase 4
- Gastroenteritis · Phase 4
- Glaucoma · Phase 2/Phase 3
- Glaucoma, Neovascular · Phase 2
- Glaucoma, Open-Angle · Phase 2
- Graves Ophthalmopathy · Phase 2/Phase 3
- Head and Neck Neoplasms · Phase 3
- Heart Failure · Phase 1
- Hematopoietic Stem Cell Transplantation · Phase 2
- Hemorrhoids · Phase 3
- Hepatitis, Alcoholic · Phase 2/Phase 3
- Hepatitis C · Phase 3
- Hepatolenticular Degeneration · Phase 4
- HIV Infections · Phase 4
- Hypovolemia · Phase 4
- Infant · Phase 2
- Inflammation · Phase 4
- Inositol · Phase 4
- Insulin Resistance · Phase 4
- Intertrigo · Early Phase 1
- Jaundice, Neonatal · Phase 1/Phase 2
- Kidney Failure, Chronic · Phase 2
- Kidney Neoplasms · Phase 2
- Leukemia · Phase 2
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 2
- Malaria · Phase 2/Phase 3
- Melanoma · Phase 2
- Melanosis · Phase 4
- Meningitis · Phase 3
- Mucositis · Phase 2/Phase 3
- Nerve Sheath Neoplasms · Phase 2
- Obesity · Phase 2/Phase 3
- Only Child · Phase 1
- Oral Submucous Fibrosis · Phase 3
- Pancreatic Neoplasms · Phase 4
- Pediatric Obesity · Phase 4
- Pharmacology · Phase 2
- Plasma · Phase 4
- Pneumonia · Phase 3
- Respiratory Tract Infections · Phase 4
- Sepsis · Phase 3
- Stomach Neoplasms · Phase 2
- Stomatitis, Aphthous · Phase 2
- Sun Protection Factor · Phase 3
- Teratoma · Phase 3
- Tinnitus · Phase 2
- Tissue Adhesions · Phase 2
- Tobacco Use Disorder · Phase 2
- Tuberculosis, Pulmonary · Phase 3
- Tumor Suppressor Protein p53 · Phase 2
- Typhoid Fever · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Warts · Phase 3
- Zinc · Phase 4
Mechanism of action
- UnclearUnclear
Unclear unclear
Combination products
depinar
with cyanocobalamin, tannic acid
multrys
with cupric sulfate pentahydrate, manganese sulfate, selenious acid
Approval history
- approvedJul 29, 1955
Chemistry & pharmacology
SMILES
O.O.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Mg+2]- Mol. weight
- 450.63 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989640 ↗
- WikipediaSmithsonite ↗
- NCATSR4R8J0Q44B ↗
- ChEMBLCHEMBL2068884 ↗
- ChEMBLCHEMBL1201128 ↗
- ChEMBLCHEMBL1200929 ↗
- ChEMBLCHEMBL1200928 ↗
- ChEMBLCHEMBL464345 ↗
- ChEMBLCHEMBL1200471 ↗
- WikipediaZinc sulfate ↗
- WikipediaZinc oxide ↗
- WikipediaZinc chloride ↗
- WikipediaZinc acetate ↗
- ChEMBLCHEMBL1200679 ↗
- ChEMBLCHEMBL3833362 ↗
- ChEMBLCHEMBL2107145 ↗
Also known as
- almora
- almora
- anusol
- anusol
- bis(n-oxopyridine-2-thionato)zinc (ii)
- boron gluconate
- chelated zinc
- curash
- dan-gard
- de-squaman
- dextronic acid
- dextronic acid
- dextronic acid
- dextronic acid
- d-gluconate
- d-gluconic acid
- d-gluconic acid
- d-gluconic acid
- d-gluconic acid
- d-gluconic acid
- d-gluconic acid, monosodium salt
- dr.elsoms
- e576
- e576
- e650
- e650
- galzin
- galzin
- galzin
- glucomag
- gluconate
- gluconate
- gluconate
- gluconic acid
- gluconic acid
- gluconic acid
- gluconic acid
- gluconic acid
- gluconic acid
- gluconic acid, (113)indium-labeled
- gluconic acid, 1-(14)c-labeled
- gluconic acid, (14)c-labeled
- gluconic acid, (159)dysprosium-labeled salt
- gluconic acid, 6-(14)c-labeled
- gluconic acid, (99)technecium (5+) salt
- gluconic acid, aluminum (3:1) salt
- gluconic acid, ammonium salt
- gluconic acid, calcium salt
- gluconic acid, cesium(+3) salt
- gluconic acid, cobalt (2:1) salt
- gluconic acid, copper salt
- gluconic acid, fe(+2) salt, dihydrate
- gluconic acid, lanthanum(+3) salt
- gluconic acid, magnesium (2:1) salt
- gluconic acid, manganese (2:1) salt
- gluconic acid, monolithium salt
- gluconic acid, monopotassium salt
- gluconic acid, monosodium salt
- gluconic acid, potassium salt
- gluconic acid sodium salt
- gluconic acid, sodium salt
- gluconic acid, strontium (2:1) salt
- gluconic acid, tin(+2) salt
- gluconic acid, zinc salt
- glycogenic acid
- glyconic acid
- head & shoulders conditioner
- hexite
- lithium gluconate
- lithium gluconate
- lithium gluconate
- magnerot
- magnesium d-gluconate
- magnesium d-gluconate
- magnesium d-gluconate
- magnesium d-gluconate
- magnesium gluconate
- magnesium gluconate
- magnesium gluconate
- magnesium gluconate
- magnesium gluconate
- magnesium gluconate
- maltonic acid
- maltonic acid
- maltonic acid
- maltonic acid
- manganese gluconate
- monosodium d-gluconate
- monosodium d-gluconate
- monosodium d-gluconate
- monosodium d-gluconate
- monosodium d-gluconate
- óxido de cinc
- óxido de cinc
- oxyde de zinc
- oxyde de zinc
- pate a l'eau
- pennine
- pentahydroxycaproic acid
- polano's
- pyrithione zinc
- pyrithione zinc
- pyrithione zinc
- pyrithione zinc
- revlon zp11
- sebulon
- sodium gluconate
- sodium gluconate
- sodium gluconate
- sodium gluconate
- sodium gluconate
- solvazinc
- sootheye
- stiefel brand 1 of zinc pyrithione
- stiefel brand 2 of zinc pyrithione
- sudocrem
- sulfuric acid zinc salt
- (t-4)-bis(1-hydroxy-2(1h)- pyridinethionato-o,s)zinc
- vision
- vision
- white vitriol
- white vitriol
- wilzin
- wilzin
- z.e.b.
- zinc acetate
- zinc acetate
- zinc acetate
- zinc acetate
- zinc acetate
- zinc acetate
- zinc acetate
- zinc acetate anhydrous
- zinc acetate anhydrous
- zinc acetate anhydrous
- zinc acetate anhydrous
- zinc acetate dihydrate
- zinc (as oxide)
- zinc (as oxide)
- zinc (as zinc oxide)
- zinc (as zinc oxide)
- zincate
- zinc bromide
- zinc bromide
- zinc carbonate
- zinc carbonate
- zinc carbonate
- zinc chloride
- zinc chloride
- zinc chloride
- zinc chloride
- zinc chloride
- zinc chloride
- zinc chloride
- zinc chloride
- zinc chloride, (65)zn-labeled
- zinc citrate
- zinc citrate
- zinc citrate
- zinc diacetate
- zinc dichloride
- zincfrin
- zincfrin
- zinc gluconate
- zinc gluconate
- zinc gluconate
- zinc gluconate
- zinc gluconate
- zinc gluconate trihydrate
- zinc gluconate trihydrate
- zinc gluconate trihydrate
- zinci oxydum
- zinci oxydum
- zinc lactate
- zinc lactate
- zinc oleate
- zinc oleate
- zincomed
- zincomed
- zincon (zinc pyrithione)
- zincosol
- zinc oxide
- zinc oxide
- zinc oxide
- zinc oxide
- zinc oxide
- zinc oxide
- zinc oxide
- zinc oxide
- zinc oxide
- zinc oxide
- zinc oxide
- zinc oxide.
- zinc oxide.
- zinc phenolsulphonate
- zinc phenolsulphonate
- zincpolyanemine
- zinc pyridinethione
- zinc pyrithione
- zinc pyrithione
- zinc pyrithione
- zinc pyrithione
- zinc sulfate
- zinc sulfate
- zinc sulfate
- zinc sulfate
- zinc sulfate
- zinc sulfate
- zinc sulfate
- zinc sulfate heptahydrate
- zinc sulfate heptahydrate
- zinc sulfate heptahydrate
- zinc sulfate heptahydrate
- zinc sulfate heptahydrate
- zinc sulfate heptahydrate
- zinc sulfite
- zinc sulfite
- zinc sulphate
- zinc sulphate
- zinc sulphate
- zincum oxydatum
- zincum oxydatum
- zinc undecylenate
- zinc undecylenate
- zinc undecylenate
- zinc white
- zinc white
- zindole
- zind sulfate
- zing
- zinkoxid
- zinkoxid
- zn co
- znp
- zn sulf co
- zpt
- z span
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06075134 | N/A | Nov 30, 2023 | Cairo University |
| NCT06042010 | N/A | Jan 5, 2023 | Alexandria University |
| NCT05465434 | Phase 3 | Aug 1, 2022 | Tanta University |
| NCT05605886 | Early Phase 1 (Phase 1) | May 20, 2022 | Cairo University |
| NCT05157711 | Phase 3 | Nov 25, 2021 | Church & Dwight Company, Inc. |
| NCT05543603 | N/A | Apr 13, 2021 | Hospital Universitario Infanta Elena, Universidad Autonoma de Madrid, University of Valencia |
| NCT04371406 | Phase 3 | May 2, 2020 | Assistance Publique - Hôpitaux de Paris |
| NCT03406793 | N/A | Feb 20, 2018 | International Center for Diarrheal Disease Research, Johns Hopkins University, University of California, San Francisco, University of Colorado, Denver |
| NCT03283813 | Phase 4 | Feb 5, 2018 | University of Eastern Piedmont |
| NCT03158168 | Phase 3 | Nov 1, 2017 | Assiut University |
| NCT02422368 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2017 | Isfahan University |
| NCT03135522 | Phase 2 | Jun 15, 2017 | American Lung Association, Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI) |
| NCT03098810 | Phase 4 | Apr 1, 2017 | Ain Shams University |
| NCT03078842 | N/A | Jan 23, 2017 | Harvard University, Muhimbili University, World Health Organization |
| NCT03672513 | N/A | Sep 8, 2016 | University of Granada |
| NCT02856269 | N/A | Sep 1, 2016 | Case Western Reserve University, National Institutes of Health (NIH), University Hospitals Cleveland Medical Center |
| NCT02805257 | Phase 2 | Jun 1, 2016 | Asociación para Evitar la Ceguera en México, Bascom Palmer Eye Institute, Sun Yat-Sen University, University of California, San Francisco, University of Colorado, Denver, University of Maryland, University of North Carolina at Chapel Hill |
| NCT02715466 | Phase 4 | Apr 1, 2016 | B. Braun |
| NCT02751320 | N/A | Feb 1, 2016 | GlaxoSmithKline |
| NCT03112382 | Phase 4 | Nov 1, 2015 | Cairo University |
Organizations
Research & Development (142)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| All India Institute of Medical Sciences | Academic/Hospital | 5 | 1 | 2 | 2003 |
| International Center for Diarrheal Disease Research | Academic/Hospital | 5 | 4 | 3 | 1999 |
| Johns Hopkins University | Academic/Hospital | 5 | 2 | 3 | 2000 |
| Alcon | For profit | 3 | 2 | 2 | 2008 |
| Baylor University | Academic/Hospital | 3 | 1 | 2 | 2004 |
| Cairo University | Academic/Hospital | 3 | 3 | 3 | 2015 |
| Mayo Clinic | Academic/Hospital | 3 | 2 | 2 | 2002 |
| National Institutes of Health (NIH) | Government | 3 | 1 | 3 | 2001 |
| University of Bergen | Academic/Hospital | 3 | 3 | 1 | 2003 |
| University of California, San Francisco | Academic/Hospital | 3 | 3 | 2 | 2008 |
| University of Sao Paulo | Academic/Hospital | 3 | 3 | 1 | 2007 |
| Aga Khan University | Academic/Hospital | 2 | 2 | 1 | 2007 |
| Ain Shams University | Academic/Hospital | 2 | 2 | 2 | 2014 |
| Allegro Ophthalmics, LLC | For profit | 2 | 2 | 1 | 2014 |
| Assiut University | Academic/Hospital | 2 | 2 | 2 | 2014 |
| Babylon University | Academic/Hospital | 2 | 1 | 1 | 2011 |
| B. Braun | For profit | 2 | 2 | 1 | 2010 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 2 | 0 | 1 | 2001 |
| Boston University | Academic/Hospital | 2 | 1 | 1 | 2007 |
| Duke University | Academic/Hospital | 2 | 1 | 1 | 2014 |
Marketing (22)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Abraxis | For profit | NDA2 | May 5, 1987 |
| Apicore | For profit | MKTG | Apr 14, 2025 |
| Apotex | For profit | MKTG | Jun 10, 2024 |
| Armour & Company | For profit | MKTG | Feb 22, 1980 |
| Armour & Company | For profit | NDA2 | Feb 22, 1980 |
| Aspiro | For profit | MKTG | May 1, 2025 |
| Daiichi Sankyo | For profit | NDA2 | Jul 18, 2019 |
| Eton Pharmaceuticals, Inc. | For profit | MKTG | Jan 28, 1997 |
| Exela Pharma Sciences, LLC. | For profit | MKTG | May 21, 2021 |
| Fosun | For profit | MKTG | May 3, 2022 |
| Fresenius | For profit | MKTG | Dec 27, 2022 |
| Gland Pharma Ltd | For profit | MKTG | May 3, 2022 |
| Gland Pharma Ltd | For profit | SYN | May 3, 2022 |
| Hospira | For profit | NDA2 | Jun 26, 1986 |
| Nivagen Pharmaceuticals Inc. | For profit | MKTG | Jul 5, 2024 |
| STIRA | For profit | MKTG | Jun 10, 2025 |
| Sankyo | For profit | MKTG | Jul 18, 2019 |
| Somerset Pharmaceuticals | For profit | SYN | Oct 16, 2024 |
| Somerset Pharmaceuticals | For profit | MKTG | Jul 17, 2024 |
| Teva | For profit | NDA2 | Jan 28, 1997 |
| Teva | For profit | NDA | Jan 28, 1997 |
| Zydus Discovery DMCC | For profit | MKTG | Aug 22, 2023 |